X4 Pharmaceuticals, Inc. (XFOR)
3.73
-0.12
(-3.12%)
USD |
NASDAQ |
Jun 10, 16:00
3.72
-0.01
(-0.27%)
After-Hours: 20:00
X4 Pharmaceuticals Total Assets (Quarterly) : 270.28M for March 31, 2026
Total Assets (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 270.28M |
| December 31, 2025 | 290.46M |
| September 30, 2025 | 163.56M |
| June 30, 2025 | 105.17M |
| March 31, 2025 | 130.01M |
| December 31, 2024 | 146.45M |
| September 30, 2024 | 178.16M |
| June 30, 2024 | 210.61M |
| March 31, 2024 | 112.18M |
| December 31, 2023 | 147.26M |
| September 30, 2023 | 173.29M |
| June 30, 2023 | 173.40M |
| March 31, 2023 | 124.40M |
| December 31, 2022 | 155.59M |
| September 30, 2022 | 113.41M |
| June 30, 2022 | 81.02M |
| March 31, 2022 | 99.62M |
| December 31, 2021 | 117.18M |
| September 30, 2021 | 120.52M |
| Date | Value |
|---|---|
| June 30, 2021 | 141.66M |
| March 31, 2021 | 161.04M |
| December 31, 2020 | 122.87M |
| September 30, 2020 | 133.13M |
| June 30, 2020 | 142.53M |
| March 31, 2020 | 153.72M |
| December 31, 2019 | 160.70M |
| September 30, 2019 | 109.54M |
| June 30, 2019 | 133.51M |
| March 31, 2019 | 62.55M |
| December 31, 2018 | 9.944M |
| September 30, 2018 | 45.90M |
| June 30, 2018 | 57.21M |
| March 31, 2018 | 69.22M |
| December 31, 2017 | 81.25M |
| September 30, 2017 | 37.16M |
| June 30, 2017 | 39.52M |
| March 31, 2017 | 10.98M |
| December 31, 2016 | 7.604M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Kyverna Therapeutics, Inc. | 257.02M |
| Arrowhead Pharmaceuticals, Inc. | 2.268B |
| Oncolytics Biotech, Inc. | 8.161M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.179B |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 101.83M |
| Shareholders Equity (Quarterly) | 168.45M |
| Debt to Equity Ratio | 0.4586 |
| Current Ratio | 10.18 |
| Net Debt Paydown Yield | 0.04% |